| dbo:abstract |
4-HO-MPMI (also known as 4-Hydroxy-N-methyl-(α,N-trimethylene)-tryptamine or lucigenol) is a tryptamine derivative that is a psychedelic drug. It was developed by the team led by David Nichols from Purdue University in the late 1990s. This compound produces hallucinogen-appropriate responding in animal tests with a similar potency to the amphetamine-derived psychedelic DOI, and has two enantiomers, with only the (R)-enantiomer being active. The binding affinity for 5-HT2A receptor is 13 ± 2 nM (Ki [125I]DOI). It is reported at doses starting at 0.5 mg and 1.0-1.5 mg seem to be psychedelic doses. The duration it is reported between six and eight hours. The effects, still not too documented, are OEV/CEV, sedation and anxiety. (en) |
| dbo:casNumber |
250672-65-2 |
| dbo:fdaUniiCode |
46OU9HLZ35 |
| dbo:pubchem |
10466404 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/4-HO-N-Me-TMT.png?width=300 |
| dbo:wikiPageID |
18054613 (xsd:integer) |
| dbo:wikiPageLength |
3370 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1106304091 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Purdue_University dbr:Enantiomer dbr:David_E._Nichols dbr:Psychedelic_drug dbc:Designer_drugs dbr:SN-22 dbr:MPMI_(drug) dbr:Tryptamine dbr:4-HO-McPeT dbr:4-HO-pyr-T dbr:5-MeO-MPMI dbr:5-MeO-pyr-T dbr:Amphetamine dbr:2,5-dimethoxy-4-iodoamphetamine dbc:Psychedelic_tryptamines dbr:CP-135,807 dbr:Chemical_derivative |
| dbp:c |
14 (xsd:integer) |
| dbp:casNumber |
250672 (xsd:integer) |
| dbp:chemspiderid |
8641815 (xsd:integer) |
| dbp:drugName |
4 (xsd:integer) |
| dbp:h |
17 (xsd:integer) |
| dbp:iupacName |
-3 (xsd:integer) |
| dbp:legalDe |
NpSG (en) |
| dbp:legalUk |
Class A (en) |
| dbp:n |
2 (xsd:integer) |
| dbp:o |
1 (xsd:integer) |
| dbp:pubchem |
10466404 (xsd:integer) |
| dbp:smiles |
OC1=C2C=CNC2=CC=C1 (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
XYRKPZYRLSWABB-LLVKDONJSA-N (en) |
| dbp:unii |
46 (xsd:integer) |
| dbp:verifiedfields |
changed (en) |
| dbp:verifiedrevid |
449774285 (xsd:integer) |
| dbp:watchedfields |
changed (en) |
| dbp:width |
180 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:Drugbox dbt:Hallucinogens dbt:Reflist dbt:Short_description dbt:Tryptamines dbt:Unreliable_source? dbt:Cascite dbt:Chemspidercite dbt:Fdacite dbt:Stdinchicite |
| dcterms:subject |
dbc:Designer_drugs dbc:Psychedelic_tryptamines |
| gold:hypernym |
dbr:Drug |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug umbel-rc:DrugProduct |
| rdfs:comment |
4-HO-MPMI (also known as 4-Hydroxy-N-methyl-(α,N-trimethylene)-tryptamine or lucigenol) is a tryptamine derivative that is a psychedelic drug. It was developed by the team led by David Nichols from Purdue University in the late 1990s. This compound produces hallucinogen-appropriate responding in animal tests with a similar potency to the amphetamine-derived psychedelic DOI, and has two enantiomers, with only the (R)-enantiomer being active. (en) |
| rdfs:label |
4-HO-MPMI (en) |
| owl:sameAs |
freebase:4-HO-MPMI yago-res:4-HO-MPMI wikidata:4-HO-MPMI dbpedia-sh:4-HO-MPMI dbpedia-sr:4-HO-MPMI https://global.dbpedia.org/id/4HxcZ |
| prov:wasDerivedFrom |
wikipedia-en:4-HO-MPMI?oldid=1106304091&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/4-HO-N-Me-TMT.png |
| foaf:isPrimaryTopicOf |
wikipedia-en:4-HO-MPMI |
| foaf:name |
4-Hydroxy-N-methyl-(α,N-trimethylene)tryptamine (en) |
| is dbo:wikiPageRedirects of |
dbr:C14H17N2O dbr:Lucigenol dbr:4-Hydroxy-N-methyl-(α,N-trimethylene)tryptamine |
| is dbo:wikiPageWikiLink of |
dbr:List_of_designer_drugs dbr:List_of_psychedelic_drugs dbr:MPMI_(drug) dbr:C14H17N2O dbr:CP-135807 dbr:4-HO-McPeT dbr:5-MeO-MPMI dbr:Lucigenol dbr:4-Hydroxy-N-methyl-(α,N-trimethylene)tryptamine |
| is foaf:primaryTopic of |
wikipedia-en:4-HO-MPMI |
